Atea Pharmaceuticals Rises After Hepatitis C Data; 2026 Readouts Eyed
Atea Pharmaceuticals shares gained Wednesday as the antiviral drug maker put out new data, saying the results support using its experimental hepatitis C treatment alongside widely used medicines. The stock, traded on Nasdaq, was recently at $4.60, up 7 cents, about 1.5%. It had moved between $4.49 and $4.66 during the day. Market cap was close to $364 million.